Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

STED Safer Therapeutics Through Early Toxicity Detection

Coordinator
Queen Mary University of London, United Kingdom
Runs
1 November 2026 to 30 April 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335624

What the project is doing

In the project's own words, from its summary on CORDIS.

The development of safer and more effective medicines is constrained by the late detection of drug-induced toxicity, one of the principal causes of attrition during drug development and a major contributor to escalating costs. Existing screening strategies are primarily designed to identify target engagement, whereas toxic liabilities frequently become apparent only during advanced preclinical studies or clinical trials, resulting in costly failures and significant delays in bringing new therapies to patients.

This ERC Proof-of-Concept project capitalises on discoveries arising from the ERC Consolidator Grant Form and Function of the Mitochondrial Retrograde Response (FIRM, ERC-2018-COG-819600), which identified mitochondrial pathway 18 (MP-18), a previously unrecognised and highly conserved stress-response pathway that is rapidly activated following cellular injury. Importantly, MP-18 is triggered at an early stage of mitochondrial dysfunction, preceding conventional indicators of cellular toxicity.

We will translate this discovery into a first-in-class live-cell toxicity detection platform by engineering mammalian reporter cell lines that generate a dual-colour fluorescent readout upon MP-18 activation. This ratiometric system enables real-time quantification of cellular stress while simultaneously measuring compound efficacy and toxicity within a single assay. Unlike existing approaches, the platform eliminates the need for endpoint measurements, pathogen manipulation, or separate toxicity assays, making it inherently scalable and readily compatible with high-throughput drug screening.

The project will deliver a validated MP-18 reporter assay prototype positioned for integration into pharmaceutical discovery pipelines, supported by a robust intellectual property strategy and a clear route to commercialisation. By enabling the earlier and more reliable identification of toxic compounds, this technology has the potential to reduce attrition, lower development costs, substantially reduce reliance on animal testing in line with the 3Rs principles, and accelerate the development of safer and more effective medicines.

Topics

Who is involved

OrganisationCityCountryRole
Queen Mary University of LondonLondonUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI